Shire Pharmaceuticals International, a leading biopharmaceutical company headquartered in Ireland (IE), has established itself as a key player in the global healthcare landscape since its founding in 1986. Specialising in rare diseases and complex conditions, Shire focuses on innovative therapies that address unmet medical needs, particularly in areas such as neuroscience, immunology, and genetic disorders. With a strong presence in North America, Europe, and Asia, Shire has achieved significant milestones, including its acquisition by Takeda Pharmaceutical Company in 2019, which further solidified its market position. The company is renowned for its unique portfolio of products, including treatments for attention deficit hyperactivity disorder (ADHD) and rare genetic disorders, setting it apart in the biopharmaceutical industry. Shire's commitment to advancing patient care continues to drive its success and reputation as a trusted leader in the field.
We don't have data for Shire Pharmaceuticals International, but we can show you information about their parent organization instead.
View parent company